PDF(Pubmed)
Abstract：
BACKGROUND: Coronary heart disease and type 2 diabetes mellitus (T2DM) frequently coexist, creating a complex and challenging clinical scenario, particularly when complicated with acute myocardial infarction (AMI).
OBJECTIVE: To examine the effects of dapagliflozin combined with sakubactrovalsartan sodium tablets on myocardial microperfusion.
METHODS: In total, 98 patients were categorized into control (n = 47) and observation (n = 51) groups. The control group received noxital, while the observation group was treated with dapagliflozin combined with noxital for 6 months. Changes in myocardial microperfusion, blood glucose level, cardiac function, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) level, growth differentiation factor-15 (GDF-15) level, and other related factors were compared between the two groups. Additionally, the incidence of major adverse cardiovascular events (MACE) and adverse reactions were calculated.
RESULTS: After treatment, in the observation and control groups, the corrected thrombolysis in myocardial infarction frame counts were 37.12 ± 5.02 and 48.23 ± 4.66, respectively. The NT-proBNP levels were 1502.65 ± 255.87 and 2015.23 ± 286.31 pg/mL, the N-terminal pro-atrial natriuretic peptide (NT-proANP) levels were 1415.69 ± 213.05 and 1875.52 ± 241.02 ng/mL, the GDF-15 levels were 0.87 ± 0.43 and 1.21 ± 0.56 g/L, and the high-sensitivity C-reactive protein (hs-CRP) levels were 6.54 ± 1.56 and 8.77 ± 1.94 mg/L, respectively, with statistically significant differences (P < 0.05). The cumulative incidence of MACEs in the observation group was significantly lower than that in the control group (P < 0.05). The incidence of adverse reactions was 13.73% (7/51) in the observation group and 10.64% (5/47) in the control group, with no statistically significant difference (P > 0.05).
CONCLUSIONS: Dapagliflozin combined with nocinto can improve myocardial microperfusion and left ventricular remodeling and reduce MACE incidence in patients with post-AMI heart failure and T2DM. The underlying mechanism may be related to the reduction in the expression levels of NT-proANP, GDF-15, and hs-CRP.
OBJECTIVE: To examine the effects of dapagliflozin combined with sakubactrovalsartan sodium tablets on myocardial microperfusion.
METHODS: In total, 98 patients were categorized into control (n = 47) and observation (n = 51) groups. The control group received noxital, while the observation group was treated with dapagliflozin combined with noxital for 6 months. Changes in myocardial microperfusion, blood glucose level, cardiac function, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) level, growth differentiation factor-15 (GDF-15) level, and other related factors were compared between the two groups. Additionally, the incidence of major adverse cardiovascular events (MACE) and adverse reactions were calculated.
RESULTS: After treatment, in the observation and control groups, the corrected thrombolysis in myocardial infarction frame counts were 37.12 ± 5.02 and 48.23 ± 4.66, respectively. The NT-proBNP levels were 1502.65 ± 255.87 and 2015.23 ± 286.31 pg/mL, the N-terminal pro-atrial natriuretic peptide (NT-proANP) levels were 1415.69 ± 213.05 and 1875.52 ± 241.02 ng/mL, the GDF-15 levels were 0.87 ± 0.43 and 1.21 ± 0.56 g/L, and the high-sensitivity C-reactive protein (hs-CRP) levels were 6.54 ± 1.56 and 8.77 ± 1.94 mg/L, respectively, with statistically significant differences (P < 0.05). The cumulative incidence of MACEs in the observation group was significantly lower than that in the control group (P < 0.05). The incidence of adverse reactions was 13.73% (7/51) in the observation group and 10.64% (5/47) in the control group, with no statistically significant difference (P > 0.05).
CONCLUSIONS: Dapagliflozin combined with nocinto can improve myocardial microperfusion and left ventricular remodeling and reduce MACE incidence in patients with post-AMI heart failure and T2DM. The underlying mechanism may be related to the reduction in the expression levels of NT-proANP, GDF-15, and hs-CRP.
摘要：
背景：冠心病和2型糖尿病（T2DM）经常共存，创造一个复杂而具有挑战性的临床场景，特别是并发急性心肌梗死（AMI）时。
目的：观察达格列净联合萨库巴曲缬沙坦片对心肌微灌注的影响。
方法：总共，98例患者分为对照组（n=47）和观察组（n=51）。对照组接受noxital,观察组给予达格列净联合诺瑟尔治疗6个月。心肌微灌注的变化，血糖水平，心功能,N末端脑钠肽原(NT-proBNP)水平,生长分化因子-15(GDF-15)水平，比较两组的其他相关因素。此外,计算主要不良心血管事件(MACE)和不良反应的发生率.
结果：治疗后，观察组和对照组,校正后的心肌梗死溶栓帧数分别为37.12±5.02和48.23±4.66。NT-proBNP水平分别为1502.65±255.87和2015.23±286.31pg/mL,N末端前心房利钠肽（NT-proANP）水平分别为1415.69±213.05和1875.52±241.02ng/mL，GDF-15水平为0.87±0.43和1.21±0.56g/L，高敏C反应蛋白(hs-CRP)水平分别为6.54±1.56和8.77±1.94mg/L,分别,差异具有统计学意义(P<0.05)。观察组的MACEs累积发生率明显低于对照组(P<0.05)。观察组不良反应发生率为13.73%(7/51),对照组不良反应发生率为10.64%(5/47)。差异无统计学意义(P>0.05)。
结论：达格列净联合诺康宁可改善AMI后心力衰竭和T2DM患者心肌微灌注和左心室重构，降低MACE发生率。潜在的机制可能与降低NT-proANP的表达水平有关。GDF-15和hs-CRP。
目的：观察达格列净联合萨库巴曲缬沙坦片对心肌微灌注的影响。
方法：总共，98例患者分为对照组（n=47）和观察组（n=51）。对照组接受noxital,观察组给予达格列净联合诺瑟尔治疗6个月。心肌微灌注的变化，血糖水平，心功能,N末端脑钠肽原(NT-proBNP)水平,生长分化因子-15(GDF-15)水平，比较两组的其他相关因素。此外,计算主要不良心血管事件(MACE)和不良反应的发生率.
结果：治疗后，观察组和对照组,校正后的心肌梗死溶栓帧数分别为37.12±5.02和48.23±4.66。NT-proBNP水平分别为1502.65±255.87和2015.23±286.31pg/mL,N末端前心房利钠肽（NT-proANP）水平分别为1415.69±213.05和1875.52±241.02ng/mL，GDF-15水平为0.87±0.43和1.21±0.56g/L，高敏C反应蛋白(hs-CRP)水平分别为6.54±1.56和8.77±1.94mg/L,分别,差异具有统计学意义(P<0.05)。观察组的MACEs累积发生率明显低于对照组(P<0.05)。观察组不良反应发生率为13.73%(7/51),对照组不良反应发生率为10.64%(5/47)。差异无统计学意义(P>0.05)。
结论：达格列净联合诺康宁可改善AMI后心力衰竭和T2DM患者心肌微灌注和左心室重构，降低MACE发生率。潜在的机制可能与降低NT-proANP的表达水平有关。GDF-15和hs-CRP。
